Study M1076
Study name | Wang D 2023 |
Title | Plasma metabolomics and network pharmacology identified glutamate, glutamine, and arginine as biomarkers of depression under Shuganjieyu capsule treatment |
Overall design | The aim of this study was to investigate the effect of Shuganjieyu capsule treatment on depression and search for essential metabolites. In this study, 23 patients with depression (depression group) and 26 age- and gender-matched healthy controls (control group) were recruited. Patients in the depression group were treated with Shuganjieyu capsule for 8 weeks. Plasma was subjected to 1H NMR metabolomics analysis. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-24 scores between 8 and 23 |
Sample size | 49 |
Tissue | Peripheral; Blood; Plasma; |
Platform | NMR; NMR: Avance III 600-MHz NMR spectrometers (Bruker, Billerica, MA); |
PMID | |
DOI | |
Citation | Wang D, Gao Y, Li Y, et al. Plasma metabolomics and network pharmacology identified glutamate, glutamine, and arginine as biomarkers of depression under Shuganjieyu capsule treatment. J Pharm Biomed Anal. 2023 Aug 5;232:115419. |
Metabolite | L-Glutamic acid; Glycine; L-Isoleucine; L-Lactic acid; L-Glutamine; L-Arginine; N-acetyl glycoprotein; |
